Diagnostic Test for Cancer Susceptibility
- Detailed Technology Description
- Researchers at the University of California have discovered a novel tumor suppressor gene, CDK4I, that inhibits the activity of the oncogene CDK4. The CDK4I gene is mutated in the majority of malignant melanomas, gliomas, non-small cell lung cancers, and leukemias. CDK4I is located immediately adjacent to the methylthioadenosine phosphorylase (MTAse) gene, on chromosome 9p21. Deficiencies in CDK4I and MTAse have previously been shown to be directly related to the onset of certain cancers. One of the U.S. patent applications that is available for licensing was involved in two interference proceedings with two parties before the U.S.P.T.O. The Regents of the University of California won the proceedings on the claims involved in both interferences. The Regents believes that these claims are not dominated by the U.S. patent claims of the other party to the interferences. However, any party must obtain its own opinion of counsel regarding the extent of issued claim coverage. The technology comprises diagnostic methods to detect mutations of the CDK4I gene as well as detecting deficiencies in the expression products of the gene. In addition, the technology also provides for the detection of mutations and altered gene product of the CDK4I-linked gene MTAse. The technique can be used to diagnose individuals who carry mutations in CDK4I or MTAse genes, and are therefore more susceptible to developing malignant melanoma and certain other familial and environmental cancers. Successful early detection of a pre-cancerous condition can enable effective measures to be taken to prevent subsequent cancer progression. The methods can also be applied to the screening and identification of anti-cancer molecules that will target aberrant CDK4I and MTAse gene products. In addition, these discoveries will be applied to research in the field of cell cycle regulation. While there have been significant advances in cancer therapies of late, early detection and subsequent treatment greatly increases the survival rate. The prevalence of mutations in the CDK4I gene in malignant cells makes it an important diagnostic target for early detection of cancer susceptibility. The procedures allow for the rapid analysis of CDK4I and MTAse gene and gene products for detection of mutations that may lead to uncontrolled cell proliferation and subsequent cancer progression.
- Supplementary Information
- Patent Number: US6689561B1
Application Number: US1994227800A
Inventor: Carson, Dennis A. | Nobori, Tsutomu
Priority Date: 14 Apr 1994
Priority Number: US6689561B1
Application Date: 14 Apr 1994
Publication Date: 10 Feb 2004
IPC Current: C12N001509 | A61K003800 | A61P003500 | C07H002104 | C07K001447 | C07K001482 | C07K001618 | C07K001632 | C12P002102 | C12P002108 | C12Q000102 | C12Q000168 | G01N003353
US Class: 43500614 | 435006 | 4350912 | 435194 | 4353201 | 435325 | 5360231 | 53602433
Assignee Applicant: The Regents of the University of California
Title: Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
Usefulness: Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
Novelty: Cyclin dependent kinase inhibitor gene, related vectors and antibodies useful for diagnosis, assessing predisposition and treatment of cancers
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application No.
- 6689561
- Others
-
Other Information
Research interests can be found at: http://cancer.ucsd.edu/Research/summaries/dcarson.asp
Additional Technologies by these Inventors
Tech ID/UC Case
19628/1994-A91-0
Related Cases
1994-A91-0
- *Abstract
-
None
- *IP Issue Date
- Feb 10, 2004
- *Principal Investigator
-
Name: Dennis Carson
Department:
Name: Tsutomu Nobori
Department:
- Country/Region
- USA
For more information, please click Here
